All In Biotech

Drug Trial Radar · NCT04821102

Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration

Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy in Patients With K-L Grade III Knee Osteoarthritis After JOINTSTEM Administration

Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

21

Planned (sponsor's estimate)

Start

Jul 1, 2023

Primary completion

Aug 1, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
R-BioIndustry
Sponsor type
Industry
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm cartilage regeneration through arthroscopy after a single administration of autologous Adipose Tissue derived Mesenchymal stem cells(JOINTSTEM) in patients with degenerative arthritis of K-L grade 3

Conditions

  • Degenerative Arthritis
  • Knee Arthritis

Interventions

  • JOINTSTEMBiological

    JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection under ultrasonic guided

  • SalineDrug

    saline, 1 time injection under ultrasonic guided

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ArthroscopyTime frame: 48 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bethesda Hospital

    Yangsan, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.